Medical radioisotopes manufacturer Niowave Inc and Ratio Therapeutics Inc, a clinical-stage pharmaceutical company developing radiopharmaceuticals for cancer treatment, announced on Tuesday a supply agreement for Actinium-225.

Under this agreement, Niowave will supply cGMP Actinium-225 to support Ratio's development of targeted radiotherapeutics. The supply agreement provides Ratio with further reliable sourcing of Actinium-225 to support ongoing clinical trial activities and future programme advancement.

Niowave says that Actinium-225 is an alpha-emitting radioisotope with significant potential in targeted cancer therapies. When attached to targeting molecules, Actinium-225 delivers potent alpha radiation directly to cancer cells while minimising damage to surrounding healthy tissue. As demand for targeted alpha therapies continues to grow, establishing a reliable domestic supply of Actinium-225 remains essential to clinical development and future commercialisation.